Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

BACKGROUND: Pembrolizumab is effective as first-line therapy against advanced non-small cell lung cancer (NSCLC) in patients with programmed death ligand-1 (PD-L1) expression levels ≥50% [1]. However, it is not effective in all patients, and the factors predicting responses among this population rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Mitsunori, Tamiya, Motohiro, Fujimoto, Daichi, Tamiya, Akihiro, Suzuki, Hidekazu, Hirano, Katsuya, Fukuda, Yasushi, Yokoyama, Toshihide, Kominami, Ryota, Kanazu, Masaki, Uchida, Junji, Hara, Satoshi, Yamashita, Shuji, Tomioka, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998183/
https://www.ncbi.nlm.nih.gov/pubmed/32013910
http://dx.doi.org/10.1186/s12885-020-6582-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998183/
https://www.ncbi.nlm.nih.gov/pubmed/32013910
http://dx.doi.org/10.1186/s12885-020-6582-4

Ejemplares similares